The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
A compendium of placebo-controlled trials of the risks/benefits of pharmacological treatments for insomnia: The empirical basis for U.S. clinical practice
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemiologic Study of Sleep Disturbances and Psychiatric Disorders: An Opportunity for Prevention?
Ford, D. E. (1989) · JAMA · doi:10.1001/jama.1989.03430110069030 · Cited by 2,252
Psychological and behavioral treatment of insomnia: update of the recent evidence (1998-2004)
Morin, C. M., Bootzin, R. R., Buysse, D. J., Edinger, J. D., Espie, C. A., & Lichstein, K. L. (2006) · Sleep · doi:10.1093/sleep/29.11.1398 · Cited by 1,345
Behavioral and Pharmacological Therapies for Late-Life Insomnia: A Randomized Controlled Trial
Morin, C. M., Colecchi, C., Stone, J., Sood, R., & Brink, D. (1999) · JAMA · doi:10.1001/jama.281.11.991 · Cited by 1,095
Tsuno, N., Besset, A., & Ritchie, K. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n1008 · Cited by 1,084
Fava, M., McCall, W. V., Krystal, A., Wessel, T., Rubens, R., Caron, J., Amato, D., & Roth, T. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.01.016 · Cited by 480
Residual symptoms in depressed patients who respond acutely to fluoxetine
Nierenberg, A. A., Keefe, B. R., Leslie, V. C., Alpert, J. E., Pava, J. A., Worthington, J. J., Rosenbaum, J. F., & Fava, M. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0403 · Cited by 470
Benzodiazepines and Zolpidem for Chronic Insomnia: A Meta-analysis of Treatment Efficacy
Nowell, P. D. (1997) · JAMA · doi:10.1001/jama.1997.03550240060035 · Cited by 451
Walsh, J. K., Krystal, A. D., Amato, D. A., Rubens, R., Caron, J., Wessel, T. C., Schaefer, K., Roach, J., Wallenstein, G., & Roth, T. (2007) · Sleep · doi:10.1093/sleep/30.8.959 · Cited by 239
Self-citationROTH, T., WALSH, J., KRYSTAL, A., WESSEL, T., & ROEHRS, T. (2005) · Sleep Medicine · doi:10.1016/j.sleep.2005.06.004 · Cited by 230
Self-citationTrazodone for antidepressant-associated insomnia
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.7.1069 · Cited by 227
Research works printed but not linked: 100
- Walsh, 2004, Drugs used to treat insomnia in 2002: regulatory-based rather than evidence-based medicine, Sleep, 27, 14441, 10.1093/sleep/27.8.1441 · DOI
- Walsh, 1998, Subjective hypnotic efficacy of trazodone and zolpidem in DSM-III-R primary insomnia, Hum Psychopharmacol, 13, 191, 10.1002/(SICI)1099-1077(199804)13:3<191::AID-HUP972>3.0.CO;2-X · doi:10.1002/(sici)1099-1077(199804)13:3<191::aid-hup972>3.0.co;2-x
- Krystal, 2004, The changing perspective of chronic insomnia management, J Clin Psychiatry, 65, 20
- Hohagen, 1994, Prevalence of insomnia in elderly general practice attenders and the current treatment modalities, Acta Psychiatr Scand, 90, 102, 10.1111/j.1600-0447.1994.tb01563.x · DOI
- Hohagen, 1993, Prevalence and treatment of insomnia in general practice. A longitudinal study, Eur Arch Psychiatry Clin Neurosci, 242, 329, 10.1007/BF02190245 · DOI · Paper page
- Locniskar, 1990, Oxidative versus conjugative biotransformation of temazepam, Biopharm Drug Dispos, 11, 499, 10.1002/bdd.2510110604 · doi:10.1002/bdd.2510110604
- Greenblatt, 1989, Pharmacokinetic determinants of dynamic differences among three benzodiazepine hypnotics. Flurazepam, temazepam, and triazolam, Arch Gen Psychiatry, 46, 326, 10.1001/archpsyc.1989.01810040032006 · DOI
- Yamazaki, 2007, Different effects of light food on pharmacokinetics and pharmacodynamics of three benzodiazepines, quazepam, nitrazepam and diazepam, J Clin Pharm Ther, 32, 31, 10.1111/j.1365-2710.2007.00795.x · doi:10.1111/j.1365-2710.2007.00795.x
- Miura, 2004, In vitro metabolism of quazepam in human liver and intestine and assessment of drug interactions, Xenobiotica, 34, 1001, 10.1080/02772240400015214 · doi:10.1080/02772240400015214
- Greenblatt, 2005, Clonazepam pharmacokinetics: comparison of subcutaneous microsphere injection with multiple-dose oral administration, J Clin Pharmacol, 45, 1288, 10.1177/0091270005280861 · DOI
- Crevoisier, 2003, Comparative single-dose pharmacokinetics of clonazepam following intravenous, intramuscular and oral administration to healthy volunteers, Eur Neurol, 49, 173, 10.1159/000069089 · DOI
- Nims, 1997, In vivo induction and in vitro inhibition of hepatic cytochrome P450 activity by the benzodiazepine anticonvulsants clonazepam and diazepam, Drug Metab Dispos, 25, 750
- Fukasawa, 2007, Effects of genetic polymorphism of cytochrome P450 enzymes on the pharmacokinetics of benzodiazepines, J Clin Pharm Ther, 32, 333, 10.1111/j.1365-2710.2007.00829.x · DOI
- Erdman, 2007, Absence of food effect on the extent of alprazolam absorption from an orally disintegrating tablet, Pharmacotherapy, 27, 1120, 10.1592/phco.27.8.1120 · doi:10.1592/phco.27.8.1120
- Greenblatt, 1989, Age and gender effects on chlordiazepoxide kinetics: relation to antipyrine disposition, Pharmacology, 38, 327, 10.1159/000138553 · DOI
- Gustavson, 1990, The clinical pharmacokinetics of single doses of estazolam, Am J Med, 88, 2S, 10.1016/0002-9343(90)90278-L · DOI
- Greenblatt, 2006, Dynamics and kinetics of a modified-release formulation of zolpidem: comparison with immediate-release standard zolpidem and placebo, J Clin Pharmacol, 46, 1469, 10.1177/0091270006293303 · DOI
- Pichard, 1995, Oxidative metabolism of zolpidem by human liver cytochrome P450S, Drug Metab Dispos, 23, 1253, 10.1016/S0090-9556(25)06824-2 · DOI
- Greenblatt, 1998, Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo, Clin Pharmacol Ther, 64, 553, 10.1016/S0009-9236(98)90139-4 · DOI
- Lake, 2002, Metabolism of zaleplon by human liver: evidence for involvement of aldehyde oxidase, Xenobiotica, 32, 835, 10.1080/00498250210158915 · DOI
- Fernandez, 1993, Pharmacokinetics of zopiclone and its enantiomers in Caucasian young healthy volunteers, Drug Metab Dispos, 21, 1125, 10.1016/S0090-9556(25)08209-1 · DOI
- Ziegler, 1978, Contribution to the pharmacokinetics of amitriptyline, J Clin Pharmacol, 18, 462, 10.1002/j.1552-4604.1978.tb01572.x · doi:10.1002/j.1552-4604.1978.tb01572.x
- Richelson, 1984, Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro, J Pharmacol Exp Ther, 230, 94, 10.1016/S0022-3565(25)21446-X · DOI · Paper page
- Venkatakrishnan, 1998, Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro: dominance of CYP 2C19 and 3A4, J Clin Pharmacol, 38, 112, 10.1002/j.1552-4604.1998.tb04399.x · DOI
- Ghahramani, 1997, Cytochromes P450 mediating the N-demethylation of amitriptyline, Br J Clin Pharmacol, 43, 137, 10.1046/j.1365-2125.1997.05382.x · DOI
- Karim, 2006, Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia, J Clin Pharmacol, 46, 140, 10.1177/0091270005283461 · DOI
- Greenblatt, 2007, Age and gender effects on the pharmacokinetics and pharmacodynamics of ramelteon, a hypnotic agent acting via melatonin receptors MT1 and MT2, J Clin Pharmacol, 47, 485, 10.1177/0091270006298602 · DOI
- Kirchheiner, 2002, Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers, Pharmacogenetics, 12, 571, 10.1097/00008571-200210000-00010 · doi:10.1097/00008571-200210000-00010
- Virtanen, 1980, Single dose pharmacokinetics of doxepin in healthy volunteers, Acta Pharmacol Toxicol (Copenh), 47, 371, 10.1111/j.1600-0773.1980.tb01575.x · DOI
- Miller, 1988, Kinetics, brain uptake, and receptor binding characteristics of flurazepam and its metabolites, Psychopharmacology (Berl), 94, 386, 10.1007/BF00174694 · DOI
- Mendelson, 2007, Combining pharmacologic and nonpharmacologic therapies for insomnia, J Clin Psychiatry, 68, 19
- Greenblatt, 1979, Lorazepam kinetics in the elderly, Clin Pharmacol Ther, 26, 103, 10.1002/cpt1979261103 · DOI
- Rotzinger, 1998, Human CYP2D6 and metabolism of m-chlorophenylpiperazine, Biol Psychiatry, 44, 1185, 10.1016/S0006-3223(97)00483-6 · doi:10.1016/s0006-3223(97)00483-6
- Banks, 1988, Mediation of serotonin-induced analgesia by the 5HT2 receptor in the pentobarbital anesthetized mouse model, Brain Res Bull, 21, 887, 10.1016/0361-9230(88)90022-6 · doi:10.1016/0361-9230(88)90022-6
- Greenblatt, 1987, Trazodone kinetics: effect of age, gender, and obesity, Clin Pharmacol Ther, 42, 193, 10.1038/clpt.1987.132 · DOI
- Ishida, 1995, Effects of various factors on steady state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine, Int Clin Psychopharmacol, 10, 143, 10.1097/00004850-199510030-00002 · DOI
- Rotzinger, 1999, Metabolism of some “second”- and “fourth”-generation antidepressants: iprindole, viloxazine, bupropion, mianserin, maprotiline, trazodone, nefazodone, and venlafaxine, Cell Mol Neurobiol, 19, 427, 10.1023/A:1006953923305 · doi:10.1023/a:1006953923305
- Nilsen, 1992, Single dose pharmacokinetics of trazodone in healthy subjects, Pharmacol Toxicol, 71, 150, 10.1111/j.1600-0773.1992.tb00535.x · doi:10.1111/j.1600-0773.1992.tb00535.x
- Cohen, 1997, Pharmacokinetics of mirtazapine from orally administered tablets: influence of a high-fat meal, Eur J Drug Metab Pharmacokinet, 22, 103, 10.1007/BF03189792 · DOI
- Bookstaff, 1996, Effects of doxylamine succinate on thyroid hormone balance and enzyme induction in mice, Toxicol Appl Pharmacol, 141, 584, 10.1006/taap.1996.0325 · doi:10.1006/taap.1996.0325
- Toothaker, 2000, Absence of pharmacokinetic interaction between orally co-administered naproxen sodium and diphenhydramine hydrochloride, Biopharm Drug Dispos, 21, 229, 10.1002/bdd.234 · doi:10.1002/bdd.234
- Akutsu, 2007, Identification of human cytochrome p450 isozymes involved in diphenhydramine N-demethylation, Drug Metab Dispos, 35, 72, 10.1124/dmd.106.012088 · doi:10.1124/dmd.106.012088
- Luna, 1989, Doxylamine and diphenhydramine pharmacokinetics in women on low-dose estrogen oral contraceptives, J Clin Pharmacol, 29, 257, 10.1002/j.1552-4604.1989.tb03323.x · doi:10.1002/j.1552-4604.1989.tb03323.x
- Schotte, 1996, Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding, Psychopharmacology, 124, 57, 10.1007/BF02245606 · DOI · Paper page
- Sekine, 1999, Correlations between in vitro affinity of antipsychotics to various central neurotransmitter receptors and clinical incidence of their adverse drug reactions, Eur J Clin Pharmacol, 55, 583, 10.1007/s002280050676 · DOI
- Bymaster, 1996, Radioreceptor binding profile of the atypical antipsychotic olanzapine, Neuropsychopharmacology, 14, 87, 10.1016/0893-133X(94)00129-N · DOI · Paper page
- He, 1995, A pharmacological, pharmacokinetic and clinical overview of risperidone, a new antipsychotic that blocks serotonin 5-HT2 and dopamine D2 receptors, Int Clin Psychopharmacol, 10, 19, 10.1097/00004850-199503000-00003 · DOI
- Beasley, 1996, Olanzapine versus placebo and haloperidol: acute phase results of the north American double-blind olanzapine trial, Neuropsychopharmacology, 14, 111, 10.1016/0893-133X(95)00069-P · DOI · Paper page
- Markowitz, 2006, Pharmacokinetics of olanzapine after single-dose oral administration of standard tablet versus normal and sublingual administration of an orally disintegrating tablet in normal volunteers, J Clin Pharmacol, 46, 164, 10.1177/0091270005283839 · DOI
- Hajak, 1994, Zopiclone improves sleep quality and daytime well-being in insomniac patients: comparison with triazolam, flunitrazepam and placebo, Int Clin Psychopharmacol, 9, 251, 10.1097/00004850-199400940-00004 · DOI
- Drake, 2000, Dose–response effects of zaleplon as compared with triazolam (0.25mg) and placebo in chronic primary insomnia, Hum Psychopharmacol, 15, 595, 10.1002/hup.216 · DOI
- Fabre, 1978, Multi-clinic double-blind comparison of triazolam (Halcion) and placebo administered for 14 consecutive nights in outpatients with insomnia, J Clin Psychiatry, 39, 679
- Nair, 1990, A dose-range finding study of zopiclone in insomniac patients, Int Clin Psychopharmacol, 5, 1
- Scharf, 1990, Estazolam and flurazepam: a multicenter, placebo-controlled comparative study in outpatients with insomnia, J Clin Pharmacol, 30, 461, 10.1002/j.1552-4604.1990.tb03486.x · DOI
- Walsh, 1984, A multi-center clinical investigation of estazolam: short-term efficacy, Curr Ther Res, 36, 866
- Aden, 1983, Quazepam in the short-term treatment of insomnia in outpatients, J Clin Psychiatry, 44, 454
- Fillingim, 1979, Double-blind evaluation of the efficacy and safety of temazepam in outpatients with insomnia, Br J Clin Pharmacol, 8, 73S, 10.1111/j.1365-2125.1979.tb00461.x · DOI
- Roehrs, 1983, Dose-related effects of estazolam on sleep of patients with insomnia, J Clin Psychopharmacol, 3, 152, 10.1097/00004714-198306000-00002 · DOI
- Scharf, 1994, A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia, J Clin Psychiatry, 55, 192
- Elie, 1999, Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. Zaleplon Clinical Study Group, J Clin Psychiatry, 60, 536, 10.4088/JCP.v60n0806 · DOI · Paper page
- Roth, 2006, Zoladult Study Group. Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia, Sleep Med, 7, 397, 10.1016/j.sleep.2006.04.008 · DOI
- Walsh, 2000, A five week, polysomnographic assessment of zaleplon 10mg for the treatment of primary insomnia, Sleep Med, 1, 41, 10.1016/S1389-9457(99)00006-4 · DOI
- Krystal, 2003, Sustained efficacy of eszopiclone over six months of nightly treatment: results of a randomized, double-blind, placebo controlled study in adults with chronic insomnia, Sleep, 26, 793, 10.1093/sleep/26.7.793 · DOI · Paper page
- Zammit, 2004, Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia, Curr Med Res Opin, 20, 1979, 10.1185/174234304X15174 · DOI · Paper page
- Roth, 2007, Efficacy and safety of doxepin 1mg, 3mg, and 6mg in adults with primary insomnia, Sleep, 30, 1555, 10.1093/sleep/30.11.1555 · DOI · Paper page
- Erman, 2006, An efficacy, safety, and dose–response study of ramelteon in patients with chronic primary insomnia, Sleep Med, 7, 17, 10.1016/j.sleep.2005.09.004 · DOI · Paper page
- Walsh, 2000, Eight weeks of non-nightly use of zolpidem for primary insomnia, Sleep, 23, 1087, 10.1093/sleep/23.8.1h · DOI · Paper page
- Krystal, 2008, Long-term efficacy and safety of zolpidem extended-release 12.5mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study, Sleep, 31, 79, 10.1093/sleep/31.1.79 · DOI · Paper page
- Elie, 1990, Efficacy and safety of zopiclone and triazolam in the treatment of geriatric insomniacs, Int Clin Psychopharmacol, 5, 39
- Reeves, 1977, Comparison of triazolam, flurazepam, and placebo as hypnotics in geriatric patients with insomnia, J Clin Pharmacol, 17, 319, 10.1002/j.1552-4604.1977.tb04611.x · DOI
- Piccione, 1980, The efficacy of triazolam and chloral hydrate in geriatric insomniacs, J Int Med Res, 8, 361, 10.1177/030006058000800513 · DOI
- Sunshine, 1975, Comparison of the hypnotic activity of triazolam, flurazepam hydrochloride, and placebo, Clin Pharmacol Ther, 17, 573, 10.1002/cpt1975175573 · DOI
- Roehrs, 1985, Efficacy of a reduced triazolam dose in elderly insomniacs, Neurobiol Aging, 6, 293, 10.1016/0197-4580(85)90006-5 · DOI
- Ancoli-Israel, 1999, Zaleplon, a novel nonbenzodiazepine hypnotic, effectively treats insomnia in elderly patients without causing rebound effects, Prim Care Companion J Clin Psychiatry, 1, 114, 10.4088/PCC.v01n0404 · DOI
- Hedner, 2000, Zaleplon shortens subjective sleep latency and improves subjective sleep quality in elderly patients with insomnia. The Zaleplon Clinical Investigator Study Group, Int J Geriatr Psychiatry, 15, 704, 10.1002/1099-1166(200008)15:8<704::AID-GPS183>3.3.CO;2-J · doi:10.1002/1099-1166(200008)15:8<704::aid-gps183>3.3.co;2-j
- Scharf, 2005, A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia, Sleep, 28, 720, 10.1093/sleep/28.6.720 · DOI
- McCall, 2006, A polysomnography study of eszopiclone in elderly patients with insomnia, Curr Med Res Opin, 22, 1633, 10.1185/030079906X112741 · DOI
- Lydiard, 2006, Efficacy and tolerability of modified-release indiplon in elderly patients with chronic insomnia: results of a 2-week double-blind, placebo-controlled trial, J Clin Sleep Med, 2, 309, 10.5664/jcsm.26591 · DOI
- Roth, 2007, A 2-night, 3-period, crossover study of ramelteon's efficacy and safety in older adults with chronic insomnia, Curr Med Res Opin, 23, 1005, 10.1185/030079907X178874 · DOI
- Roth, 2006, Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia, Sleep Med, 7, 312, 10.1016/j.sleep.2006.01.003 · DOI · Paper page
- Morgan, 1990, Hypnotics in the elderly: what cause for concern?, Drugs, 40, 688, 10.2165/00003495-199040050-00004 · DOI
- Asplund, 2000, Sleep and hypnotic use in relation to perceived somatic and mental health among the elderly, Arch Gerontol Geraitr, 31, 199, 10.1016/S0167-4943(00)00075-3 · DOI
- Ohayon, 1996, The elderly, sleep habits and use of psychotropic drugs by the French population, Encephale, 5, 337
- Morgan, 1988, Prevalence, frequency and duration of hypnotic use among elderly living at home, Br Med J, 296, 601, 10.1136/bmj.296.6622.601 · DOI · Paper page
- Hayes, 2007, Polypharmacy and the geriatric patient, Clin Geriatr Med, 23, 371, 10.1016/j.cger.2007.01.002 · DOI
- Cook, 1983, Hypnotic accumulation and hangover in elderly inpatients: a controlled double-blind study of temazepam and nitrazepam, Br Med J (Clin Res Ed), 286, 100, 10.1136/bmj.286.6359.100 · DOI
- Mindell, 2006, Pharmacologic management of insomnia in children and adolescents: consensus statement, Pediatrics, 117, e1223, 10.1542/peds.2005-1693 · DOI · Paper page
- National Institutes of Health, 1984, Consensus conference. Drugs and insomnia. The use of medications to promote sleep, JAMA, 251, 2410, 10.1001/jama.251.18.2410 · DOI
- Estivill, 2002, Behavior of insomniacs and implication for their management, Sleep Med Rev, 6, S3, 10.1016/S1087-0792(02)80001-6 · DOI
- Perlis, 1997, Self-reported sleep disturbance as a prodromal symptom in recurrent depression, J Affect Disord, 42, 209, 10.1016/S0165-0327(96)01411-5 · DOI · Paper page
- Thase, 1999, Antidepressant treatment of the depressed patient with insomnia, J Clin Psychiatry, 60, 28
- Reynolds, 1997, Which elderly patients with remitted depression remain well with continued interpersonal psychotherapy after discontinuation of antidepressant medication?, Am J Psychiatry, 154, 958, 10.1176/ajp.154.7.958 · DOI
- Nolen, 1993, Hypnotics as concurrent medication in depression. A placebo-controlled, double-blind comparison of flunitrazepam and lormetazepam in patients with major depression, treated with a (tri)cyclic antidepressant, J Affect Disord, 28, 179, 10.1016/0165-0327(93)90103-Q · DOI
- Londborg, 2000, Short-term cotherapy with clonazepam and fluoxetine: anxiety, sleep disturbance and core symptoms of depression, J Affect Disord, 61, 73, 10.1016/S0165-0327(99)00195-0 · DOI · Paper page
- Krystal, 2007, Evaluation of eszopiclone discontinuation after co-therapy with fluoxetine for insomnia with co-existing depression, J Clin Sleep Med, 3, 48
- Pollack, 2008, Eszopiclone co-administered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder, Arch Gen Psychiatry, 65, 551, 10.1001/archpsyc.65.5.551 · DOI · Paper page
- Walsh, 1996, Effects of triazolam on sleep, daytime sleepiness, and morning stiffness in patients with rheumatoid arthritis, J Rheumatol, 23, 245
- Le Bon, 2003, Double-blind, placebo-controlled study of the efficacy of trazodone in alcohol post-withdrawal syndrome: polysomnographic and clinical evaluations, J Clin Psychopharmacol, 23, 377, 10.1097/01.jcp.0000085411.08426.d3 · DOI · Paper page
- Soares, 2006, Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomized controlled trial, Obstet Gynecol, 108, 1402, 10.1097/01.AOG.0000245449.97365.97 · DOI · Paper page
- Lineberger, 2006, Defining insomnia: quantitative criteria for insomnia severity and frequency, Sleep, 29, 479, 10.1093/sleep/29.4.479 · DOI
Cited by
Morin, C. M., & Benca, R. (2012) · The Lancet · doi:10.1016/s0140-6736(11)60750-2 · Cited by 976
Morin, C. M., Drake, C. L., Harvey, A. G., Krystal, A. D., Manber, R., Riemann, D., & Spiegelhalder, K. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.26 · Cited by 746
Self-citationCognitive and behavioral therapies in the treatment of insomnia: A meta-analysis
van Straten, A., van der Zweerde, T., Kleiboer, A., Cuijpers, P., Morin, C. M., & Lancee, J. (2018) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2017.02.001 · Cited by 676
Wilson, S., Nutt, D., Alford, C., Argyropoulos, S., Baldwin, D., Bateson, A., Britton, T., Crowe, C., Dijk, D.-J., Espie, C., et al. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881110379307 · Cited by 634
Self-citation(Mis)perception of Sleep in Insomnia: A Puzzle and a Resolution
Harvey, A. G., & Tang, N. K. Y. (2012) · Psychological Bulletin · doi:10.1037/a0025730 · Cited by 529
Metadata
- Authors
- Krystal, A. D.
- Venue
- Sleep Medicine Reviews
- Publisher
- Elsevier BV
- Published
- 2009-08
- Volume
- 13
- Issue
- 4
- Pages
- 265-274
- ISSN
- 1087-0792 (ISSN-L)
- OpenAlex
- W2060446359
- Cited by
- 180
- References
- 17
- FWCI
- 16.87
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A compendium of placebo-controlled trials of the risks/benefits of pharmacological treatments for insomnia: The empirical basis for U.S. clinical practice. https://app.cochat.ai/papers/10.1016/j.smrv.2008.08.001
- The paper
- Krystal, A. D. (2009). A compendium of placebo-controlled trials of the risks/benefits of pharmacological treatments for insomnia: The empirical basis for U.S. clinical practice. Sleep Medicine Reviews. https://doi.org/10.1016/j.smrv.2008.08.001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.